2-(4-Boc-哌嗪-1-基)-6-氟苯甲醛 | 851753-43-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 2-(4-Boc-哌嗪-1-基)-6-氟苯甲醛
• 英文名称: 4-(2-fluoro-6-formyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester
• 英文别名: 2-[4-(tert-butoxycarbonyl)-1-piperazinyl]-3-fluorobenzaldehyde；tert-Butyl 4-(2-fluoro-6-formylphenyl)piperazine-1-carboxylate
• CAS: 851753-43-0
• 化学式: C₁₆H₂₁FN₂O₃
• 分子量: 308.353
• InChiKey: QJBKIZQJOQTBCO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  49.8
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT

制备方法与用途

用途

4-(2-氟-6-甲酰基苯基)哌嗪-1-甲酸叔丁酯用作研究用化合物。

反应信息

• 作为反应物：
  描述：

  2-(4-Boc-哌嗪-1-基)-6-氟苯甲醛 在 盐酸 、 titanium(IV) tetraethanolate 、 三甲基铝 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 1-{4-[2-((S)-1-Amino-3-methyl-butyl)-6-fluoro-phenyl]-piperazin-1-yl}-3-(2,4-dichloro-phenyl)-propan-1-one
  参考文献：
  名称：

  Arylpropionylpiperazines as antagonists of the human melanocortin-4 receptor

  摘要：

  A series of 3-arylpropionylpiperazines were synthesized as antagonists of the melanocortin-4 receptor. Their potency was found to be increased by replacing the alpha-methyl substituent of the initial lead 11 with a larger s-Bu or i-Bu group. Further potency enhancement was observed when a glycine or beta-alanine was incorporated onto the benzylamine. Some compounds demonstrated good potency, moderate selectivity, and oral bioavailability. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.05.088
• 作为产物：
  描述：

  2,3-二氟苯甲醛 、 N-Boc-哌嗪 在 potassium carbonate 作用下， 以 二甲基亚砜 为溶剂， 反应 12.0h， 以8.1%的产率得到2-(4-Boc-哌嗪-1-基)-6-氟苯甲醛
  参考文献：
  名称：

  [EN] FUSED TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF
  [FR] DÉRIVÉ TRICYCLIQUE CONDENSÉ, SON PROCÉDÉ DE PRÉPARATION ET SON APPLICATION PHARMACEUTIQUE
  [ZH] 并三环类衍生物、其制备方法及其在医药上的应用

  摘要：

  一种涉及化学药物技术领域的并三环类衍生物、其制备方法及其在医药上的应用。所述并三环类衍生物是蛋白聚糖酶2(ADAMTS-5，Aggrecanase-2)的抑制剂。一种包含这些化合物的药物组合物以及将该化合物用于制备治疗骨关节炎等疾病的药物中的用途。

  公开号：

  WO2022007866A1

文献信息

• Ligands of melanocortin receptors and compositions and methods related thereto
  申请人：Tucci C. Fabio

  公开号：US20050119252A1

  公开（公告）日：2005-06-02

  Compounds which function as melanocortin receptor ligands and having utility in the treatment of melanocortin receptor-based disorders. The compounds have the following structure (I): including stereoisomers, prodrugs, and pharmaceutically acceptable salts thereof, wherein m, n, q, s, R 1 , R 1a , R 1b , R 2 , R 3 , R 4a , R 4b , R 5a , R 5b , X 1 , X 2 , X 3 , X 4 and Ar are as defined herein. Pharmaceutical compositions containing a compound of structure (I), as well as methods relating to the use thereof, are also disclosed.

  这是一种功能为黑素皮质素受体配体的化合物，可用于治疗基于黑素皮质素受体的疾病。该化合物具有以下结构（I）：包括立体异构体，前药和其药学上可接受的盐，其中m，n，q，s，R1，R1a，R1b，R2，R3，R4a，R4b，R5a，R5b，X1，X2，X3，X4和Ar的定义如本文所述。还公开了含有结构（I）化合物的药物组成物，以及与其使用相关的方法。
• [EN] FUSED TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF<br/>[FR] DÉRIVÉ TRICYCLIQUE CONDENSÉ, SON PROCÉDÉ DE PRÉPARATION ET SON APPLICATION PHARMACEUTIQUE<br/>[ZH] 并三环类衍生物、其制备方法及其在医药上的应用
  申请人：SHENZHEN SALUBRIS PHARM CO LTD

  公开号：WO2022007866A1

  公开（公告）日：2022-01-13

  一种涉及化学药物技术领域的并三环类衍生物、其制备方法及其在医药上的应用。所述并三环类衍生物是蛋白聚糖酶2(ADAMTS-5，Aggrecanase-2)的抑制剂。一种包含这些化合物的药物组合物以及将该化合物用于制备治疗骨关节炎等疾病的药物中的用途。
• Design, Synthesis, In Vitro, and In Vivo Characterization of Phenylpiperazines and Pyridinylpiperazines as Potent and Selective Antagonists of the Melanocortin-4 Receptor
  作者：Joe A. Tran、Wanlong Jiang、Fabio C. Tucci、Beth A. Fleck、Jenny Wen、Yang Sai、Ajay Madan、Ta Kung Chen、Stacy Markison、Alan C. Foster、Sam R. Hoare、Daniel Marks、John Harman、Caroline W. Chen、Melissa Arellano、Dragan Marinkovic、Haig Bozigian、John Saunders、Chen Chen

  DOI：10.1021/jm701137s

  日期：2007.12.13

  Benzylamine and pyridinemethylamine derivatives were synthesized and characterized as potent and selective antagonists of the melanocortin-4 receptor (MC4R). These compounds were also profiled in rodents for their pharmacokinetic properties. Two compounds with diversified profiles in chemical structure, pharmacological activities, and pharmacokinetics, 10 and 12b, showed efficacy in an established murine cachexia model. For example, 12b had a K-i value of 3.4 nM at MC4R, was more than 200-fold selective over MC3R, and had a good pharmacokinetic profile in mice, including high brain penetration. Moreover, 12b was able to stimulate food intake in the tumor-bearing mice and reverse their lean body mass loss. Our results provided further evidence that a potent and selective MC4R antagonist with appropriate pharmacokinetic properties might potentially be useful for the treatment of cancer cachexia.
• [EN] LIGANDS OF MELANOCORTIN RECEPTORS AND COMPOSITIONS AND METHODS RELATED THERETO<br/>[FR] LIGANDS DE RECEPTEURS DE LA MELANOCORTINE, COMPOSITIONS ET PROCEDES ASSOCIES
  申请人：NEUROCRINE BIOSCIENCES INC

  公开号：WO2005042516A3

  公开（公告）日：2005-12-01
• Practical Asymmetric Synthesis of α-Branched 2-Piperazinylbenzylamines by 1,2-Additions of Organometallic Reagents to <i>N</i>-<i>tert</i>-Butanesulfinyl Imines
  作者：Wanlong Jiang、Chen、Dragan Marinkovic、Joe A. Tran、Caroline W. Chen、L. Melissa Arellano、Nicole S. White、Fabio C. Tucci

  DOI：10.1021/jo051514p

  日期：2005.10.1

  2-[4-(tert-Butoxycarbonyl)piperazinyl]benzylidene-tert-butanesulfinamides underwent nucleophilic 1,2-addition with different organometallic reagents to give highly diastereomerically enriched adducts. X-ray crystallography of the resulting alpha-branched N-Boc-2-piperazinylbenzyl-tert-butanesulfinamides confirms different mechanisms depending on the organometallic reagent used. Differential deprotection of the N-Boc and the tert-butanesulfinamides was investigated, and the dehydration byproducts have been identified and characterized. To avoid the formation of byproducts in the acidic deprotection step, the N-tert-butanesulfinamide group was converted to the corresponding N-tert-butanesulfonamide (Bus), which allowed for clean orthogonal deprotection. The efficient synthesis and deprotection of the N-Boc-2-piperazinylbenzyl-tert-butanesulfinamides herein described constitutes an attractive method for extensive structure-activity studies in the search for novel ligands of the human melanocortin 4 receptor.